Healio

FDA grants fast track designation to KT-621 for moderate to severe eosinophilic asthma

The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according ...
Healio

STAT5, STAT6 activate Th9 cells to drive allergic inflammation

Please provide your email address to receive an email when new articles are posted on . The STAT5 and STAT6 transcription factors activate Th9 cells. Th9 cells produce the IL-9 cytokine, which causes ...
Nasdaq

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

Kymera Therapeutics, Inc. KYMR announced that its investigational New Drug (IND) application for pipeline candidate, KT-621, has been cleared by the FDA. KT-621 is an investigational first-in-class ...
MPR

Oral STAT6 Degrader KT-621 Fast Tracked for Eosinophilic Asthma Treatment

STAT6 degradation is expected to provide a clinical benefit for patients with Type 2 inflammatory diseases, including asthma.
BioWorld

Recludix Pharma gives update on STAT6 program

Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors ...
Nasdaq

Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program

Nurix Therapeutics secures a $15 million license extension from Sanofi for its STAT6 program, totaling $127 million to date. Nurix Therapeutics announced that Sanofi has exercised its option to ...
News Medical

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a ...